CeriBell, Inc. (CBLL) vs Kura Oncology, Inc. (KURA)
A side-by-side comparison of CeriBell, Inc. and Kura Oncology, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
CBLL
CeriBell, Inc.
$24.63HealthcareDelayed quote: Oct 6, 2026, 10:00 AM EDT
KURA
Kura Oncology, Inc.
$10.58HealthcareDelayed quote: Oct 6, 2026, 10:00 AM EDT
Total return — CBLL vs KURA
growth of $100 · dividends reinvested · last 2yCBLL -0.6% (-0.3%/yr)KURA -42.8% (-24.4%/yr)CBLL compounded faster over this window
CBLL KURA
CBLL vs KURA: by the numbers
- •KURA is the larger company ($939M vs $935M market cap).
- •Both run net losses; CBLL's is the smaller (-64.73% vs -384.30% net margin).
Metrics side by side
Valuation
| Metric | CBLL | KURA |
|---|---|---|
| P/S ratio | 9.17 | 12.16 |
| P/B ratio | 7.28 | 19.39 |
Profitability
| Metric | CBLL | KURA |
|---|---|---|
| Gross margin | 88.90% | 94.73% |
| Operating margin | -68.62% | -449.94% |
| Net margin | -64.73% | -384.30% |
| ROE | -51.43% | -612.78% |
| ROIC | -46.54% | -67.13% |
Growth (annualized)
| Metric | CBLL | KURA |
|---|---|---|
| Total return CAGR (5Y) | N/A | -10.73% |
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.